Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Dr Lechleiter of Eli Lilly Calls For Full Introduction of Premium for Development of New Drugs
March 21, 2011
- GSK: Arixtra for Treatment of Acute DVT, Acute PTE
March 21, 2011
- NIBIO Opens Toxicogenomics DB
March 21, 2011
- Bayer Aims to Launch Rivaroxaban in 2012 in Japan
March 14, 2011
- Ajinomoto Aims at Pharma Sales of ¥87.4 Bil. in FY2013
March 14, 2011
- Drastic Reform Necessary to Strengthen Japan's Competitiveness: Mr Mitani of Novartis
March 14, 2011
- Eisai Discontinues Promotion of Zonegran in the US
March 14, 2011
- Cervarix in Short Supply
March 14, 2011
- Eisai Postpones NHI Price Listing, Launching of NerBlock
March 14, 2011
- New Drugs Improve Range of Options for Osteoporosis: 4
March 14, 2011
- Eli Lilly Japan Posts Record-High Sales of ¥134,471 Mil. in 2010
March 14, 2011
- Wholesalers Wither, While Makers Thrive - Effects of New NHI Pricing System?
March 14, 2011
- Sawai to Terminate Negotiations with Kyorin
March 14, 2011
- Japan's Ethical Drug Market Grew 0.2% in 2010: IMS Japan
March 14, 2011
- Ranbaxy to Market Levofloxacin, Ofloxacin in Singapore: Daiichi Sankyo
March 14, 2011
- Takeda Licenses PDE1 Inhibitors from ITI
March 14, 2011
- Japan's Biosimilars Market Has Strong Growth Potential: Mr George of Sandoz
March 14, 2011
- Terumo Acquires CaridianBCT for US$2.6 Bil.
March 14, 2011
- Memantine, Galantamine Enter NHI Price List
March 14, 2011
- EC to Maintain Approval of Avastin + Paclitaxel for Metastatic Breast Cancer
March 14, 2011
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…